FORA Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

FORA Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,040	Closed	-$280K	–	665
2022 Q4	$280K	Buy	+6,040	New	+$238K	0.05%	384
2021 Q3	–	Sell	-6,964	Closed	-$664K	–	750
2021 Q2	$664K	Buy	6,964 +5,217	+299%	+$544K	0.12%	206
2021 Q1	$199K	Buy	+1,747	New	+$238K	0.07%	288
2020 Q2	–	Sell	-3,391	Closed	-$151K	–	1234
2020 Q1	$151K	Buy	+3,391	New	+$176K	0.03%	518

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FORA Capital's RARE Position: Q1 2023 in Review

FORA Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 6,040 shares — an estimated $280K sold.

FORA Capital first reported a position in RARE in Q1 2020 and held it in 4 quarters. The position peaked at $664K in Q2 2021. 228 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

FORA Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
FORA Capital sold 6,040 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $280K.
FORA Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and held it in 4 quarters.
FORA Capital's Ultragenyx Pharmaceutical position peaked at $664K in Q2 2021.
228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on FORA Capital's 13F filing for Q1 2023, filed 12 May 2023.